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Assessment of PERV transmission across an alginate barrier used for the encapsulation of 
porcine islets. 
Abstract 
Subcutaneous implantation of a macroencapsulated patch containing human allogenic islets 
has been successfully used to alleviate type 1 diabetes mellitus (T1DM) in a human recipient 
without the need for immunosuppression.  The use of encapsulated porcine islets to treat 
T1DM has also been reported. Although no evidence of pathogen transfer using this 
technology has been reported to date, we deemed it appropriate to determine if the 
encapsulation technology would prevent the release of virus, in particular, the porcine 
endogenous retrovirus (PERV). To do this, we cultured HEK293 (human epithelial kidney) 
and ST (swine testis) cells with macro-encapsulated pig islets embedded in an alginate 
patch, macro encapsulated PK15 (swine kidney epithelial) cells embedded in an alginate 
patch and free PK15 cells. Cells and supernatant were harvested at weekly time points from 
the cultures for up to 60 days and screened for evidence of PERV release using qRT-PCR to 
detect PERV RNA and SG-PERT to detect reverse transcriptase. No PERV virus, or evidence of 
PERV replication, was detected in the culture medium of HEK293 or pig cells cultured with 
encapsulated porcine islets. Increased PERV activity relative to the background was not 
detected in ST cells cultured with encapsulated PK15 cells. However, PERV was detected in 1 
of the 3 experimental replicates of HEK293 cells cultured with encapsulated PK15 cells. Both 
HEK293 and ST cells cultured with free PK15 cells showed an increase in reverse 
transcriptase (RT) detection. Thus, with the exception of one replicate, there does not 
appear to be evidence of transmission of replication competent PERV from the 
encapsulated islet cells or the positive control PK15 cells across the alginate barrier. The 
detection of PERV in one experimental replicate using encapsulated PK15 cells would 
suggest the alginate barrier of this replicate may have become compromised, emphasizing 




Alginate encapsulation of porcine islet cells proposes to permit the implantation of porcine 
islets as a treatment for type 1 diabetes mellitus (T1DM) in humans, whilst negating the 
need for immune suppression and reducing the risk of zoonosis. Microencapsulation i.e. 
entrapment of individual islets or small groups of islets within spherical capsules (150-1500 
µm) offers better oxygenation and overall diffusion for islet cells while macroencapsulation 
i.e. holding the islets in a single major device (also referred to as a patch) offers the 
advantage of easy retrieval and even fresh cell replenishment if necessary. Alginate is 
probably the most studied biomaterial for islet encapsulation due to its biocompatibility, 
selective permeability and the possibility to use it in both micro- and macroencapsulation 
techniques. In 2011, Basta et al. were the first to report successful microencapsulated islet 
allotransplantation in 4 non immunosuppressed diabetic patients with improvement of 
glycemia and HbA1c as well as reduced exogenous insulin requirements over a follow-up 
period of 3 years1. Human clinical trials of microencapsulated porcine islets conducted in 
New Zealand (NZ) and Argentina have also reported no evidence of pathogen transmission 
but limited efficacy, with patients exhibiting a ≥50% reduction in hypoglycemic episodes 
after 1 year when compared with control groups 2,3. 
The alginate-encapsulated monolayer device is composed of decellularized allogeneic 
(human fascia lata) or xenogeneic (porcine acellular dermis) collagen on which porcine islets 
are seeded. The ensemble is then embedded in alginate to constitute a patch of macro-
encapsulated islets. Non-human primate studies have demonstrated this approach as 
successful in correcting chemically induced diabetes for up to 6 months4. Despite the in vivo 
success of T1DM correction using encapsulated porcine islets, some concerns still remain in 
regards to safety, in particular the possible transmission of porcine endogenous retrovirus 
(PERV). Data from the NZ trial2 and Argentinian trial5 have demonstrated an absence of 
PERV in recipients of porcine encapsulated islets. However, it is worth noting that in both 
instances the human and primate recipients were immunocompetent. Thus, it is difficult to 
determine if the absence of PERV is due to the impermeability of the alginate to the virus or 
the efficiency of the immune system in targeting PERV escaping the patch. Given the lack of 
studies examining permeability of alginate patches to viruses, for this study, we deemed it 
appropriate to determine if the encapsulation technology would prevent the release of 
PERV using an in-vitro co-culture model. 
  
Materials and Methods: 
 
Isolation and preparation of islets 
Pancreatic islets were isolated from adult Landrace (2-3 year old) pigs (RA-SE genetics, 
Belgium) and cultured in vitro for 24-72 hours as previously described6 before undergoing 
encapsulation. 5000 islet equivalents (IEQ) or 25000 cells (PK15) were seeded on a collagen 
matrix (acellular porcine dermis), covered with a 300µm mesh, stabilized with surgical clips 
and coated with 3% sterile lyophilized high mannuronic acid content (SLM) alginate solution 
with a permeability up to 150kDa (Novamatrix, Norway)7. The patch was immersed in MOPS 
(3-(N-morpholino)propanesulfonic acid) buffer + 100µM CaCl2 for 7 minutes to allow 
alginate polymerization, then washed in MOPS for 5 minutes and transferred to CMRL 
culture medium (Mediatech, USA) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 1% penicillin and 1% streptomycin (stock concentration 10,000U/ml; all from 
Westburg, Netherlands). 
 
Co-culture for PERV transmission 
HEK293 (ATCC® CRL-1573) or ST (ATCC® CRL-1746) cells (5x104/well) were seeded in the 
lower compartment of Transwell 6-well plates (Corning, USA) with 2ml of dulbecco’s 
modified eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 1% penicillin and 1% streptomycin (stock concentration 10,000U/ml; all from 
Westburg, Netherlands). Patches containing islets or PK15 (ATCC® CCL-33) cells were placed 
in the insert (upper compartment) with 2ml of DMEM. For positive controls the upper 
compartment was seeded with 2.5x104 PK15 cells without encapsulation. Supernatants, 
passed through a 0.45µm Acrodisc syringe filter (VWR, Belgium), were collected weekly (in 
triplicate) from the lower compartment for an 8 week period to check for viral transmission 
by detection of RT, viral RNA and intact virus. The target cells were passaged over the study 
period and refreshed using 50% conditioned media.  ST cells were split at a ratio of 1:6, 
HEK293 and PK15 cells were split at a ratio of 1:35.  PK15 cells used were checked for RT 
release to indicate active PERV replication by SG-PERT, prior to utilization and maintained in 
a separate plate throughout the study.  
 PERV screening  
The presence of PERV RNA and reverse transcriptase (RT) were used as indicators of PERV 
release from donor cells (encapsulated or free), into the cell medium shared with target 
cells. Supernatant samples were assayed for the presence of PERV RNA using a TaqMan 
based qRT-PCR targeting the pol region using QuantiTect® virus reagents (Qiagen, Crawley, 
UK) and Viia7 real time cycler (Thermo Fisher, Paisley, UK), primers and cycling conditions 
are previously described7. SG-PERT was used to detect reverse transcriptase (RT), using 
murine leukemia virus RT as a standard and a method previously described8. Capsid integrity 
testing was carried out to distinguish between intact virions and cell derived naked RNA or 
reverse transcriptase. This involved ultracentrifugation of samples at 200,000xg for 70 mins 
at 4°C, followed by RNase treatment of re-suspended sediment (RNase A (Qiagen Crawley, 
UK) [5U/ml] and RNase T1 (Thermo Fisher, Paisley, UK) [50U/ml]) at 37°C for 1 hour, RNase 
inactivation with 10mM DTT (Sigma-Aldrich, Gillingham, UK) at 37°C for 1 hour, viral RNA 
isolation and qRT-PCR. Western blot analysis was also carried out on HEK293 supernatants; 
15µl of culture medium was electrophoresed using 8-16% Novex™gels (Life Technologies, 
Paisley, UK), transferred to a nitrocellulose membrane and probed with a Rabbit anti-gag 
antibody [1:1000] (kindly provided by Prof Yasu Takeuchi, UCL). Provirus analysis of target 
cells was carried out on DNA isolated from cells using the DNeasy mini kit (Qiagen, Crawley, 
UK) and TaqMan qPCR with QuantiTect virus reagents® and a Viia7 real time cycler (Thermo 
Fisher, Paisley, UK), as described previously7. Statistical analysis was carried out using an 
unpaired student’s t-test.  
Results  
 
As described in the methods, supernatant samples were collected on a weekly basis from 
each experiment 1-9 in triplicate (Table 1) and assayed for PERV RNA and RT (Figures 1 and 
2).  A significant increase in RT was detected by SG-PERT analysis in ST cell culture media 
exposed to free PK15 cells (Experiment 6), in comparison to ST cell only controls 
(Experiment 8) over time (week 4 p= 0.0284, week 6 p<0.0001, week 8 p<0.0001) (Figure 
1a). However, ST cells exposed to encapsulated islet and PK15 cells did not show RT levels 
higher than the ST negative control cells at any time point over the 8 week period (Figure 
1A).  
Analysis of HEK293 culture media shows high RT levels (48266 SD± 13370µURT/ml; range 
(40,708 – 63,704µURT/ml)in cell culture supernatant from HEK293 cells exposed to free 
PK15 cells at weeks 4, 6 and 8 (Figure 1B), but no RT activity was observed in supernatant 
samples from HEK293 cells exposed to encapsulated islets or control HEK293 cells (Figure 
1B). However, low level (1123 ± 1040µURT/ml; range 301-2292µURT/ml) RT activity  
was detected in HEK293 cells exposed to encapsulated PK15 cells (Figure 1B).  
 
In order to confirm if the RT activity was due to the presence of viral RNA during replication, 
qRT-PCR analysis was carried out on HEK293 cell supernatants. Analysis  showed detectable 
PERV RNA in each replicate of HEK293 cells exposed to free PK15 cells at weeks 2, 4, 6 and 8 
(Figure 2A, 2B, 2C and 2D). PERV RNA was also detected in cells exposed to encapsulated 
PK15 cells with PERV RNA in replicates B and C observed at weeks 2 and 4 (Figure 2A and 2B) 
and replicates A, B and C at weeks 6 and 8 (Figure 2C and 2D). 
In order to determine if the detected PERV RNA and RT represented free or degraded PERV 
RNA, RT escaped from cells undergoing apoptosis or PERV virions released from cells and 
transmitted across the alginate barrier, capsid integrity testing was carried out.  This assay 
confirms the presence of PERV RNA encapsulated in an intact virion. The capsid integrity 
testing indicated that intact virions were only detectable in HEK293 cell culture media in 
cells exposed to free PK15 cells at weeks 2, 4 6 and 8 (Table 2), and only in one of the 
experimental replicates of the HEK293 cells exposed to encapsulated PK15 cells (replicate C) 
at weeks 6 and 8 (Table 2). Similarly, western blot analysis of HEK293 culture media (Figure 
3) detected PERV gag in culture media from HEK293 free PK15 exposed cells and in only one 
replicate (C) of HEK293 encapsulated PK15 exposed cells at week 8. 
In addition to testing for PERV RNA and RT in the cell supernatant, it was important to 
assess if any proviral DNA was detectable in the cells over time indicative of active infection 
and integration.  The presence of proviral DNA was confirmed in ST cells at all time points as 
to be expected due to the presence of PERV in this cell line. Likewise, proviral DNA was 
detected in the cell lysates from HEK293 cells cultured with free PK15 cells.  However, over 
the 8 week period no proviral DNA was detected in the cell lysates from HEK293 cells 






Previous work had demonstrated that this device was permeable to small molecules like 
insulin but constituted an efficient barrier to microbes or large cell fragments and impurities 
during its subcutaneous application4. The aim of this study was to assess the protective 
capacity of the alginate bio-barrier to prevent the release of PERV from encapsulated cells. 
No evidence of PERV infection, or no de novo PERV infection, was found in the HEK293 or ST 
cells co-cultured with encapsulated porcine islets.  
Indeed, there was no increase in PERV RNA or RT in supernatants taken from ST cells co-
cultured with encapsulated high level PERV producing PK15 cells. It should be noted that ST 
cells have a background RT and RNA level which is deducted to evaluate whether an 
increase has occurred or not, i.e., active infection and replication. 
Both HEK293 and pig cells cultured with free PK15 cells were positive for PERV RNA and RT, 
and the presence of PERV virions as detected by Western blot analysis. 
However, PERV RNA, RT and virus was detected in 1 of the 3 experimental replicates of 
HEK293 cells co-cultured with encapsulated PK15 cells.  
This data would suggest that alginate may represent an effective barrier to PERV escape and 
that encapsulated porcine islet cells could represent a low risk in relation to PERV. Previous 
studies have been unable to demonstrate PERV infection from islet cells in vitro to 
susceptible cell lines9,10 and in vivo studies which reported an absence of PERV in 
encapsulated porcine islet recipients2,5,7,11–16.  This would suggest that islets are low risk for 
PERV release and infection and along with encapsulation, this could reduce the risk even 
more.   Indeed, it has also been suggested that islets may not harbour many of the viral 
pathogens identified in the donor pig17. However, we recognise that this study was 
conducted for a relatively short time period of 8 weeks and that a longer study would be 
valuable in examining this further. Although, it should be noted that PK15 cells used in this 
study are high PERV producers and it is likely a lower barrier of protection is required to 
protect as against PERV transmission from islet cells.   
Unfortunately a limitation of the study is that we did not confirm the viability of the cells 
post experiment to determine if cells were still viable after the 8 week period.  We also do 
not know if the prepared device for macroencapsulation had been subject to any 
degradation or breach during the experiment.  We do know that macroencapsulated islet 
cells survive for long periods in vivo4  and that the alginate matrix used in this study has 
been fully evaluated18.  The islet cells used in these experiments were macro-encapsulated, 
which utilises alginate at a 3% concentration. In the case of islet micro-encapsulation, an 
alginate concentration of 1-1.5% is usually utilised. Whether this change in alginate 
concentration would impact the protection the device offers to PERV release remains 
unknown.  However,  the permeability of the device is thought to be related more to the 
gelling solution, rather than the alginate concentration19.  In addition, the permeability of 
this device is known to be 150KDa; previous studies have demonstrated that PERV 
transmission is significantly reduced by membranes with a nominal molecular weight cut-off 
of ≤400KDa20 or 35nm21, however RNA and/or RT have been seen to not be restricted by 
this pore size.  Nyberg et al have demonstrated that the RNA of PERV is small enough to 
cross the pores in membranes of 70kDa MWCO 20,21.  The diameter of PERV is approximately 
100nm22, therefore it is feasible that where we identify RNA and/or RT this is a valid positive 
detection based on pore size, but the alginate does appear to exclude PERV viral particles.  
Based on this, it could be proposed that in replicate C, where PERV virus was detected by 
Western blot, the device had become compromised in comparison to replicates A and B 
allowing the release of particles. Likewise, the detection of RT at each time point in the 
presence of PK15 cells may represent viability as the cells are still producing replicating 
virus.  This also highlights the importance of quality control and good manufacturing 
procedures in the production of encapsulated islet devices.  To date no in vivo transmission 
of PERV in patients receiving encapsulated islet xenografts has been reported.  Based on this 
study and previous work, it may be that the use of encapsulation/membrane filters do 
indeed protect or reduce the risk of PERV.  Further studies examining the permeabilty of 
alginate to other viruses, such as hepatitis E, could also prove valuable in understanding the 
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Figure 1: Mean values of reverse transcriptase analysis, performed by SG-PERT, of culture 
medium from n=3 replicates for weeks 2, 4, 6, 8 from a) ST co-culture experiments, where 
asterisks indicate statistical significance (*=p<0.05, ****p=<0.0001), indicating significantly 
higher RT activity only in ST cell exposed to free PK15 cells. b) HEK293 co-culture 
experiments, showing high RT activity detected at weeks 4, 6 and 8 in the media of HEK293 
cells exposed to free PK15 cells, low RT activity in the media of HEK293 cells exposed to 
encapsulated PK15 cells and no RT activity detected in the media of the other experimental 
cells. 
 
Figure 2: PERV RNA copies per ml of culture medium, as determined by qRT-PCR analysis, for 
each experimental replicates (A-C) for weeks 2 (2a), 4 (2b), 6 (2c), 8(2d) from HEK293 co-
culture experiments showing detectable PERV RNA in media from all replicates exposed to 
free PK15 cells at weeks 2,4, 6 and 8 and 2 replicates from the cells exposed to encapsulated 
PK15 cells at weeks 2 and 4 and from all 3 replicates at weeks 6 and 8.   
 
Figure 3: PERV gag protein analysis, by western blot, of HEK293 culture media co-cultured 
with encapsulated islets, encapsulated PK15 cells, free PK15 cells and negative controls at 
weeks 2, 4, 6 and 8 showing detectable PERV gag protein in the culture media of all 3 
replicates of HEK293cells exposed to free PK15 cells at weeks 4, 6, and 8 and one replicate 
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